These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6985855)

  • 21. Plasma protein binding in uremia: extraction and characterization of an inhibitor.
    Depner TA; Gulyassy PF
    Kidney Int; 1980 Jul; 18(1):86-94. PubMed ID: 7218662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
    Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
    PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in insulin binding during hemodialysis in uremic patients.
    Milutinović S; Breyer D; Molnar V; Stefović A; Janković N; Skrabalo Z; Rocić B
    Nephron; 1985; 41(4):307-13. PubMed ID: 3906417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased plasma protein binding of phenytoin in patients on valproic acid.
    Dahlqvist R; Borgå O; Rane A; Walsh Z; Sjöqvist F
    Br J Clin Pharmacol; 1979 Dec; 8(6):547-52. PubMed ID: 391256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tin-protein binding kinetics in normal and uremic plasma and its effect on dialysis fluxes.
    Maher JF; Montero G; Chieffo S
    Trans Am Soc Artif Intern Organs; 1976; 22():149-54. PubMed ID: 951835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.
    Gugler R; Mueller G
    Br J Clin Pharmacol; 1978 May; 5(5):441-6. PubMed ID: 350249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma protein binding interaction between valproic and salicylic acids in rhesus monkeys.
    Viswanathan CT; Levy RH
    J Pharm Sci; 1981 Nov; 70(11):1279-81. PubMed ID: 6795339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of carbamylation of plasma proteins and competitive displacers on drug binding in uremia.
    Calvo R; Carlos R; Erill S
    Pharmacology; 1982; 24(4):248-52. PubMed ID: 7089046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of hemodialysis on endogenous middle molecules in uremic patients.
    Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
    Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of uremia and hemodialysis on the plasma protein binding of tolmetin.
    Pritchard JF; O'Neill PJ; Affrime MB; Lowenthal DT
    Pharmacology; 1984; 29(6):312-9. PubMed ID: 6505005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
    Dasgupta A; Paul A; Wells A
    Am J Med Sci; 2001 Oct; 322(4):204-8. PubMed ID: 11678517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin.
    Rosman PM; Benn R; Kay M; Wallace EZ
    Nephron; 1984; 37(4):229-31. PubMed ID: 6462312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors.
    Dasgupta A; Emerson L
    Ther Drug Monit; 1996 Dec; 18(6):654-9. PubMed ID: 8946661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unexpected suppression of free phenytoin concentration by salicylate in uremic sera due to the presence of inhibitors: MALDI mass spectrometric determination of molecular weight range of inhibitors.
    Biddle DA; Wells A; Dasgupta A
    Life Sci; 2000; 66(2):143-51. PubMed ID: 10666010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gentamicin binding to serum and plasma proteins.
    Myers DR; DeFehr J; Bennet WM; Porter GA; Olsen GD
    Clin Pharmacol Ther; 1978 Mar; 23(3):356-60. PubMed ID: 627143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.
    Verbeeck RK; De Schepper PJ
    Clin Pharmacol Ther; 1980 May; 27(5):628-35. PubMed ID: 7371361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients.
    Sarnatskaya VV; Yushko LA; Sakhno LA; Nikolaev VG; Nikolaev AV; Grinenko DV; Mikhalovsky SV
    Artif Cells Blood Substit Immobil Biotechnol; 2007; 35(3):287-308. PubMed ID: 17573628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.